Bladder cancer
Conditions
Interventions
Case series:none
Sponsors
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with cT2-T4aNxM0 bladder urothelial carcinoma diagnosed by histopathology and imaging evaluation (patients with mixed histological tumors are required to be the dominant histological type of urothelial carcinoma); 2. The case information is complete.
Exclusion criteria
Exclusion criteria: 1. In addition to primary urothelial carcinoma, patients who also have other malignancies or have other malignancies in the past 5 years; 2. Before receiving tislelizumab and neoadjuvant chemotherapy, those who have received systemic chemotherapy, targeted or other immune checkpoint inhibitor drugs for the treatment of urothelial cancer; 3. Patients with less than 3 courses of medication prescribed in the study protocol; 4. The survival period is less than 6 months .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical complete response;pathological complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence free survival;overall survival;Side effects;complications;bladder preseration rate; | — |
Countries
China
Contacts
Public ContactWang Shaogang
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Outcome results
None listed